| Alfabs Australia Limited (AAL) ORDINARY FULLY PAID |
Industrials |
$33 |
Change in substantial holding
|
26 Feb 2026 11:12AM |
$0.295 |
$0.250 |
fallen by
15.25%
|
|
| Murray Cod Australia Limited (MCA) ORDINARY FULLY PAID |
Consumer Staple |
$33 |
Notification of cessation of securities - MCA
|
26 Feb 2026 11:05AM |
$0.510 |
$0.135 |
fallen by
73.53%
|
|
| identitii Limited (ID8) ORDINARY FULLY PAID |
Information Technology |
$3 |
Pause in Trading
|
26 Feb 2026 11:03AM |
$0.008 |
$0.004 |
fallen by
56.25%
|
|
ID8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Identitii Limited, trading under the security code ID8, has a pause in trading.
- The trading halt is pending a further announcement from the company.
- This announcement was made by ASX Listings Compliance.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Bell Financial Group Limited (BFG) ORDINARY FULLY PAID |
Financials |
$462 |
Change of Director's Interest Notice
|
26 Feb 2026 10:59AM |
$1.490 |
$1.440 |
fallen by
3.36%
|
|
| 3D Energi Limited (TDO) ORDINARY FULLY PAID |
Energy |
$42 |
Notification regarding unquoted securities - TDO
|
26 Feb 2026 10:58AM |
$0.080 |
$0.080 |
fallen by
0%
|
|
| Racura Oncology Ltd (RAC) ORDINARY FULLY PAID |
Health Care |
$461 |
Application for quotation of securities - RAC
|
26 Feb 2026 10:57AM |
$2.400 |
$2.350 |
fallen by
2.08%
|
|
| Camplify Holdings Limited (CHL) ORDINARY FULLY PAID |
Industrials |
$16 |
CHL H1FY26 Interim Results and Presentation
|
26 Feb 2026 10:50AM |
$0.335 |
$0.190 |
fallen by
43.28%
|
|
CHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Statutory net loss reduced by 62.5% to $2.93 million.
- Positive operating cash flow of $12.18 million achieved.
- Total revenue slightly decreased to $19.06 million.
- Significant cost reductions in marketing and employee benefits.
- MyWay Mutual model increased premium membership margins in ANZ.
- Completed a $3.21 million capital raise.
- Future bookings valued at $34.2 million.
- Focus on cost management and high-margin product scaling.
- German market rebounded with 30% revenue increase.
- Strategic partnership development for future growth.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
1HFY26 Results Announcement
|
26 Feb 2026 10:49AM |
$0.110 |
$0.081 |
fallen by
26.36%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- Sales increased by 60.2% in H1 FY26 compared to H1 FY25.
- First sales of Empliqâ„¢ amniotic tissue products achieved.
- NervAlign® Nerve Cuff approved for use in US DoD and VA healthcare systems.
- Regulatory approvals gained in Malaysia and Hong Kong.
- Company widened its loss to $2.7 million due to higher operational costs.
- Completed a $3.2 million capital raise to support growth initiatives.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scout Security Limited (SCT) ORDINARY FULLY PAID |
Consumer Discretionary |
$0 |
Annual Report
|
26 Feb 2026 10:49AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| ReNerve Limited (RNV) ORDINARY FULLY PAID |
Health Care |
$11 |
1HFY26 Appendix 4D and Half Year Report
|
26 Feb 2026 10:48AM |
$0.110 |
$0.081 |
fallen by
26.36%
|
|
RNV - Price-sensitive ASX Announcement
Full Release
Key Points
- ReNerve Limited reported a $2,716,555 loss for the half-year ending 31 December 2025.
- Losses increased by 47.3% compared to the previous year.
- The company is shifting focus from R&D to commercial operations.
- ReNerve's product lines, NervAlign® and Empliq, are expanding in US and Asian markets.
- There were no dividends declared during this financial period.
- The company is enhancing its presence with new partnerships and product launches.
- ReNerve aims to expand its operations in Asia Pacific and refine its US business.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Camplify Holdings Limited (CHL) ORDINARY FULLY PAID |
Industrials |
$16 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 10:46AM |
$0.335 |
$0.190 |
fallen by
43.28%
|
|
CHL - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss of $2,927,551 for the half-year ended 31 December 2025.
- Revenue decreased slightly to $19,055,500 from $19,951,782.
- Camplify Holdings Limited includes operations in multiple countries.
- Equity raised through the issue of shares increased to $88,417,795.
- Significant cash flow improvements with closing cash at $23,177,629.
- No dividends declared during the period.
- Cost reduction programs and new operations launched.
- Positive outlook for H2FY26 results.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Southern Hemisphere Mining Limited (SUH) ORDINARY FULLY PAID |
Materials |
$18 |
Broad Intersections of Mineralised Porphyry at Target K
|
26 Feb 2026 10:45AM |
$0.032 |
$0.025 |
fallen by
21.88%
|
|
SUH - Price-sensitive ASX Announcement
Full Release
Key Points
- Drillhole 26LHDD072 completed to a depth of 1,038.2m at Target K.
- Multiple broad intersections of mineralised porphyry phases identified.
- Visible copper and molybdenum observed in quartz–sulphide veinlets.
- Structural data suggests further exploration vectors south and east.
- Ongoing geophysical data processing to support exploration modeling.
- Llahuin Copper-Gold-Molybdenum Project located in Chile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Scout Security Limited (SCT) ORDINARY FULLY PAID |
Consumer Discretionary |
$0 |
Appendix 4E
|
26 Feb 2026 10:43AM |
$0.007 |
$0.007 |
fallen by
0%
|
|
| HomeCo Daily Needs REIT (HDN) ORDINARY UNITS FULLY PAID |
Real Estate |
$2,739 |
Application for quotation of securities - HDN
|
26 Feb 2026 10:41AM |
$1.295 |
$1.310 |
risen by
1.16%
|
|
| Pro Medicus Limited (PME) ORDINARY FULLY PAID |
Health Care |
$19,368 |
Change of Director's Interest Notice - Anthony Hall
|
26 Feb 2026 10:39AM |
$125.010 |
$185.390 |
risen by
48.30%
|
|
| Streamplay Studio Limited (SP8) ORDINARY FULLY PAID |
Communication Services |
$11 |
Streamplay H1 FY26 Results Summary
|
26 Feb 2026 10:38AM |
$0.010 |
$0.008 |
fallen by
15.79%
|
|
| Streamplay Studio Limited (SP8) ORDINARY FULLY PAID |
Communication Services |
$11 |
Half Yearly Report and Accounts
|
26 Feb 2026 10:38AM |
$0.010 |
$0.008 |
fallen by
15.79%
|
|
SP8 - Price-sensitive ASX Announcement
Full Release
Key Points
- Revenue increased by 85% to $8,502,721.
- Net profit after tax was $571,621, up from a loss of $177,809.
- Noodlecake Studios significantly contributed to revenue growth.
- Continued operations in Middle East & Africa and Asia Pacific.
- Cash and cash equivalents at $8.55 million as of 31 December 2025.
- Focus on cost management and operational efficiency.
- No dividends declared for the period.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| HeraMED Limited (HMD) ORDINARY FULLY PAID |
Health Care |
$42 |
Investor Presentation
|
26 Feb 2026 10:37AM |
$0.036 |
$0.036 |
fallen by
0%
|
|
| Future Generation Global Limited (FGG) ORDINARY FULLY PAID |
Financials |
$675 |
FY2025 Full Year Results Q&A Webinar
|
26 Feb 2026 10:36AM |
$1.615 |
$1.680 |
risen by
4.02%
|
|
| Ambertech Limited (AMO) ORDINARY FULLY PAID |
Information Technology |
$9 |
Investor Presentation - 1H FY26 Results
|
26 Feb 2026 10:36AM |
$0.130 |
$0.094 |
fallen by
27.69%
|
|
| WCM Global Growth Limited (WQG) ORDINARY FULLY PAID |
Financials |
$518 |
Entitlement Offer Booklet
|
26 Feb 2026 10:34AM |
$1.860 |
$1.875 |
risen by
0.81%
|
|
| Ardiden Limited (ADV) ORDINARY FULLY PAID |
Materials |
$74 |
Change in substantial holding
|
26 Feb 2026 10:33AM |
$0.495 |
$0.345 |
fallen by
30.30%
|
|
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$117 |
ACW HY26 results - XanaMIA pivotal Alzheimers trial progress
|
26 Feb 2026 10:27AM |
$0.041 |
$0.032 |
fallen by
21.95%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Completion of accelerated enrolment in XanaMIA phase 2b/3 Alzheimer's trial with 247 participants.
- Positive interim safety and efficacy analysis from DMC for XanaMIA trial.
- Open-label extension phase of XanaMIA trial to commence in Q1 2026.
- Agreement with FDA on streamlined design for pivotal trial of Xanamem 10 mg vs. placebo.
- Completion of commercial-grade manufacture of Xanamem tablets for OLE phase.
- Actinogen received $7.4 million R&D tax incentive for FY2025.
- Net loss of $11.3 million for half-year ended 31 December 2025, primarily due to R&D costs.
- Proforma cash balance of $29.7 million as of 31 December 2025.
- Planning for rapid expansion pending successful phase 2b/3 trial results.
- Xanamem shows promise as a treatment for Alzheimer's with potential safety and efficacy profile.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Actinogen Medical Limited (ACW) ORDINARY FULLY PAID |
Health Care |
$117 |
Actinogen HY2025 financial report and Appendix 4D
|
26 Feb 2026 10:26AM |
$0.041 |
$0.032 |
fallen by
21.95%
|
|
ACW - Price-sensitive ASX Announcement
Full Release
Key Points
- Actinogen Medical Limited reported a net loss after tax of $11,346,952 for the half-year ended 31 December 2025, compared to a loss of $8,168,979 for the previous year.
- The company's total revenue and other income increased to $2,107,063 from $244,406 the previous year.
- Research and development costs significantly increased to $8,902,759, reflecting ongoing clinical trials and development activities.
- The company's cash and cash equivalents decreased from $16,504,230 as of 30 June 2025 to $6,531,460 as of 31 December 2025.
- The total equity of Actinogen Medical Limited decreased from $18,335,903 as of 30 June 2025 to $8,368,615 as of 31 December 2025.
- The R&D tax rebate for FY25 amounted to $5,489,600 and was fully received by the company.
- The company issued new shares during the half-year, increasing contributed equity to $116,196,238.
- Actinogen launched an InvestorHub platform in September 2025 to enhance communication with investors.
- The report included a detailed statement of financial position and changes in equity, emphasizing the impact of R&D expenses and share-based payments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Wide Open Agriculture Ltd (WOA) ORDINARY FULLY PAID |
Consumer Staple |
$5 |
Appendix 4D and Interim Financial Report
|
26 Feb 2026 10:24AM |
$0.016 |
$0.007 |
fallen by
56.25%
|
|
WOA - Price-sensitive ASX Announcement
Full Release
Key Points
- Net loss for half-year ended 31 December 2025 was $2,052,935.
- Revenue increased by 41% to $381,225 compared to the previous year.
- Focus on cost reduction and capital management to extend cash runway.
- $1.5 million in cash held as of 31 December 2025.
- Strong demand for lupin protein isolate and development of lupin oil and fiber.
- Exploration of contract manufacturing to meet demand and reduce costs.
- Directors believe the company will continue as a going concern.
- Potential R&D tax refund, equity raising, and asset disposals identified as financial strategies.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.